Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Incorporated

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Vertex Pharmaceuticals yesterday and set a price target of $515.00. Bansal covers the H...

Vertex Pharmaceuticals (VRTX) Receives a Buy from Wells Fargo

The SPDR S&P 500 ETF Trust ($SPY) gained 0.35% on Wednesday, with support from the strong performance of certain stocks such as Tesla ($TSLA), Unit...

SPY ETF Daily Update, 12/3/2025

Scotiabank analyst Louise Chen maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $495.00. According to TipRanks, Ch...

Current Quarter	$4.34	Next Quarter	$4.07
Current Year	$16.03	Next Year	$17.52
QoQ Growth	-6.2%	YoY Growth	+9.3%
3Y EPS CAGR	-30.6%	Target Price	$492.32
Consensus	Buy	Upside	+8.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VRTX	$452.04	+1.37%	1.61M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VRTX	$452.04	+1.4%	1.61M
3
4
5
6

VRTX

VRTX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Vertex Pharmaceuticals Incorporated Data in Excel

Get Vertex Pharmaceuticals Incorporated Data in Excel